<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807481</url>
  </required_header>
  <id_info>
    <org_study_id>SMC 2011-10-131</org_study_id>
    <nct_id>NCT01807481</nct_id>
  </id_info>
  <brief_title>Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD</brief_title>
  <official_title>A Prospective,Single-arm,Multicenter Study to Evaluate the Efficacy and Safety of Mircera in Peritoneal Patients Who Already Had Been Treated With ESA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of study is to evaluate the no of patients which maintain the Hb level&#xD;
      between 9.0 ~ 12.0 g/dl during the evaluation period&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objective of study is&#xD;
&#xD;
        -  No of patients with mean Hb level of +/-1.0g/dl difference from the baseline Hb&#xD;
&#xD;
        -  Incidence of RBC transfusion during the titration and evaluation periods&#xD;
&#xD;
        -  Mean Hb during the total study period&#xD;
&#xD;
        -  Intrapatient Hb variability (mean within-patient standard deviation for Hb)&#xD;
&#xD;
        -  Frequency of Micera dose level&#xD;
&#xD;
        -  safety&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with hemoglobin 10~12 g/dl</measure>
    <time_frame>Visit 0 ~ visit 10 (10 months)</time_frame>
    <description>The primary objective of this study is to evaluate the no of patients which maintain the Hb-level between 10.0~13.0 g/dL during the evaluation period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin stability, Dose adjustment</measure>
    <time_frame>Visit0~Visit 10 (10 Months)</time_frame>
    <description>Incidence of RBC transfusion during the titration and evaluation periods Mean Hb during the total study period Intrapatient Hb variability (mean within patient standard deviations for Hb) Comparison between baseline and evaluation period mean Hb level Frequency of dose adjustments Safety</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">101</enrollment>
  <condition>PD</condition>
  <arm_group>
    <arm_group_label>Mircera Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once Monthly Mircera</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mircera</intervention_name>
    <description>Once Monthly Mircera</description>
    <arm_group_label>Mircera Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  1.≥18 yr of age&#xD;
&#xD;
          -  2.peritoneal dialysis for ≥12wk before screening and during baseline period&#xD;
&#xD;
          -  3.weekly Kt/V ≥1.8 for PD patients&#xD;
&#xD;
          -  4.Baseline Hb concentration between 9.0 and 12.0g/dl(mean of the monthly Hb values&#xD;
             determined in month -2 and -1)&#xD;
&#xD;
          -  5.stable baseline Hb concentration(defined as an absolute difference ≤2g/dl between&#xD;
             the Hb values determined in month -2 and -1)&#xD;
&#xD;
          -  6.continuous subcutaneous maintenance epoetin or darbepoetin therapy for at least 2&#xD;
             months before screening and during baseline period&#xD;
&#xD;
          -  7.adequate iron status defined as serum ferritin ≥ 100ng/ml or transferrin&#xD;
             saturation≥20%(mean of two values deteremined in month -2 and -1)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  1.Overt gastrointestinal bleeding or any other bleeding episode necessitating&#xD;
             transfusion wihin 2 months before screening during baseline pereiod&#xD;
&#xD;
          -  2.RBC transfusions within 2 months before screening or during baseline period&#xD;
&#xD;
          -  3.nonrenal causes of anemia(e.g folic acid or vitamin B12 deficiency,hemolysis)&#xD;
&#xD;
          -  4.acute infection or chronic, uncontrolled or symptomatic inflammatory disease(e.g&#xD;
             rhematoid arthritis,systemic lupus erythematosus)&#xD;
&#xD;
          -  5.C-reactive protein&gt;30mg/dl&#xD;
&#xD;
          -  6.poorly controlled hypertension necessitating interruption of epotien or darbepoetin&#xD;
             in the 6 months before screening&#xD;
&#xD;
          -  7.platelets &gt; 500X109/L&#xD;
&#xD;
          -  8.pure red cell aplasia&#xD;
&#xD;
          -  9.chronic congestive heart failure(New Yorj Heart Association class IV)&#xD;
&#xD;
          -  10.Myocardial infarction,severe or unstable coronary artery disease,stroke,severe&#xD;
             liver disease within the 3months before screening or during baseline&#xD;
&#xD;
          -  11.Life expectancy &lt; 12months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Joong Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dae Joong Kim</last_name>
    <phone>82234103441</phone>
    <email>daejoong.smc.kim@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dae Joong Kim</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dae Joong Kim</last_name>
    </contact>
    <investigator>
      <last_name>Dae Joong Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae Joon g Kim</last_name>
    </contact>
    <investigator>
      <last_name>Dae Joong Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Kim Dae Joong</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Mircera</keyword>
  <keyword>PD</keyword>
  <keyword>Maitenance</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

